COVID-19 patients management

The COVID-19 pandemic is an ongoing, unprecedented global health challenge.

bioMérieux is proud to be a part of the global response with the development of three of the first commercially available diagnostic tests for SARS-CoV-2, along with additional critical tests for COVID-19 patients management.

Every COVID-19 patient comes with a unique profile and experiences the disease differently. Patient management means asking the right questions, finding the right answers and providing appropriate care the entire length of the patient pathways.

 

A partner you can count on for COVID-19 management

 

COVID-19 patient management: A transversal approach

Patients with suspected COVID-19 present with a broad array of symptoms – many of which can also be caused by other diseases. Additionally, patients with serious COVID-19 infections frequently experience secondary opportunistic infections.

COVID-19 patient management requires the healthcare team to be alert to the patient’s varied needs from primary diagnosis to the recovery period.

Throughout the patient pathway, diagnostic tests provide vital information to support improved patient care decision-making.

 

PRIMARY DIAGNOSIS

Download brochure

ARGENE® SARS-COV-2 R-GENE® and

NUCLISENS® EXTRACTION REAGENTS

Real-time PCR test that can be run on most commercial PCR platforms

CE-IVD

Emergency Use Authorization by US FDA

Download brochure

BIOFIRE® Respiratory 2.1 Panel (RP2.1)*

BIOFIRE® Respiratory 2.1 plus Panel (RP2.1plus)**

Includes SARS-CoV-2 plus 21 other common respiratory pathogens, for use on FILMARRAY® platforms

*Emergency Use Authorization by US FDA

** CE-IVD

Download brochure

VIDAS® SARS-COV-2 IgM and

VIDAS® SARS-COV-2 IgG

Serological tests that run on VIDAS® platforms.

Two assays to better follow antibody responses.

CE-IVD

SEVERITY ASSESSMENT

VIDAS® B·R·A·H·M·S PCT™

VIDAS® D-Dimer Exclusion™ II

VIDAS® High Sensitive Troponin I

VIDAS® NT-proBNP

VIDAS® Ferritin

Inflammation, coagulation and cardiac biomarkers

NEPHROCHECK®

Acute Kidney Injury biomarker

IDENTIFY POTENTIAL CO-INFECTIONS AND SECONDARY INFECTIONS

VIDAS® B·R·A·H·M·S PCT™

Specific biomarker of severe bacterial infection and sepsis

BACT/ALERT®

Family of automated microbial detection systems and blood culture media

BIOFIRE® RP2.1 / RP2.1 plus Panel

BIOFIRE® PN/PN plus Panel

Multiplex PCR for detection of upper and lower respiratory tract infections (virus, bacteria, fungi)

PREVI® COLOR GRAM

Automated Gram staining

VITEK® MS

Mass spectrometry for identification of pathogens

Respiratory R-GENE® tests and

NUCLISENS® extraction reagents

A range of real-time PCR kits for accurate simultaneous detection of infectious agents involved in respiratory diseases

CHROMID® chromogenic media

Chromogenic media for growth and identification of pathogens

ANTIMICROBIAL TREATMENT SELECTION AND MONITORING

For potential co-infections and secondary infections

VIDAS® B·R·A·H·M·S PCT™

Specific biomarker of severe bacterial infection and sepsis

VITEK® 2

Microbial identification and Antimicrobial susceptibility testing

ETEST®

MIC for critical cases

OUTCOME ASSESSMENT / DISCHARGE

ARGENE® SARS-COV-2 R-GENE® AND NUCLISENS® EXTRACTION REAGENTS
VIDAS® SARS-COV-2 IgM and SARS-COV-2 IgG

Availability of products range is subject to local regulatory approvals, allocation priorities, supply chain policies etc. Please check with your local bioMérieux representative to know more.

 

 

DOWNLOAD THE GUIDE : DIAGNOSTIC TOOLS FOR THE MANAGEMENT OF COVID-19 PATIENTS

 

 

 

COVID-19 WEBINAR SERIES

Fascinating insights from experts around the world

bioMérieux is committed to support high quality medical education for the ultimate benefits of patients.

Head to our Medical Affairs page for our series of webinars featuring experts from around the world on SARS-CoV-2 and COVID-19.

From various specialities, they share insights, lines of investigation, emerging questions and potential solutions.

Pioneering diagnostics